NCT00838565 - Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2009

Primary Completion Date

February 2, 2012

Study Completion Date

February 2, 2012

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Placebo

intravenous infusion on three consecutive months

DRUG

dose level 1

intravenous infusion on three consecutive months

DRUG

dose level 2

intravenous infusion on three consecutive months

DRUG

dose level 3

intravenous infusion on three consecutive months

DRUG

dose level 4

intravenous infusion on 3 consecutive months

Trial Locations (8)

Complexo Hospitalario Universitario A Coruña, A Coruña

Hospital Clinico Universitario de Santiago, Santiago de Compostela

Altoona Center for Clinical Research, Duncansville

Allergy, Asthma, Arthritis, & Lung, Daytona Beach

Millennium Research, Ormond Beach

Inha University Hospital, Medicine/Rheumatology, Incheon

Seoul National University Hospital, Rheumatology, Internal Medicine, Seoul

Yonsei University College of Medicine, Severance Hospital, Clinical Trial Center, Seoul